TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00583674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 386 placebo
Description: AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 10mg/kg
Description: AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 3mg/kg
Description: AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
Study: NCT01533766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CombiflexOmega
Description: intravenously over 5 days infusion
Study: NCT04023760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Study subjects given a single-dose of apixaban 10 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Study subjects given a single-dose of apixaban 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Study subjects given a single-dose of apixaban 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Study subjects given a single-dose of apixaban 10 mg.
Study: NCT03584126

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography, ecocardiography and MRI.
Description: AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Electrocardiography, ecocardiography and MRI.
Description: AF patients and healthy adult volunteers will be examined by the study physicians and included in the study according to the inclusion criteria. After a general examination, an electrocardiography, an ecocardiography and an MRI will be performed on the AF-affected and healthy hearts, respectively.
Study: NCT01158443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: 8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Counseling
Description: 8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
Study: NCT03970824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P17
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
Study: NCT01853462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF training
Description: Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
Study: NCT01464645

Intervention type: DEVICE
Intervention: Modular Revision Hip System
Description: Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
Study: NCT01050751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Oral Lersivirine 750 mg (1 x 750 mg) single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: Oral Lersivirine 750 mg (3 x 250 mg) single dose
Study: NCT01791491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Single intravenous infusion of belatacept, 7.5 mg/kg
Study: NCT02325024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Study: NCT01533766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven
Description: intravenously over 5 days infusion
Study: NCT03552094

Intervention type: OTHER
Intervention: Blood donations of hemochromatosis or polycythemia patients
Description: Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
Study: NCT03204877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study: NCT01442337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8597
Description: one time IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8597
Description: one time IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8597
Description: one time IV dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one time IV dose
Study: NCT03943290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein
Study: NCT03571360

Intervention type: OTHER
Group type: OTHER
Intervention: PD-L1 positive vs PD-L1 negative NSCLC patients
Description: Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
Study: NCT04430361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol
Description: 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
Study: NCT03970824

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Humira
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
Study: NCT02593968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon a-2b Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03748342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Second-Generation Laryngeal Mask Airway
Description: A second-generation LMA will be used for airway management (instead of ETT).
Study: NCT04430361

Intervention type: DRUG
Group type: OTHER
Intervention: 5-HT3 receptor antagonist
Description: 5-HT3 receptor antagonist 2.5mg/iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonist
Description: 5-HT3 receptor antagonist 2.5mg/iv

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
Study: NCT00933439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
Study: NCT01783197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT04749576

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saffron supplement for IBD
Description: anti inflammatory effect

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saffron supplement for IBD
Description: anti inflammatory effect

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saffron supplement for IBD
Description: anti inflammatory effect
Study: NCT01812122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Study: NCT01783197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT03552094

Intervention type: OTHER
Intervention: Blood donations of healthy donors
Description: Blood samples are from blood donations of healthy donors.
Study: NCT01339663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT01853891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dim light at night
Study: NCT01812122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study: NCT02423460

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threonine
Description: Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
Study: NCT03701204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare Rewards
Description: Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule.
Study: NCT01162304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Oxycodone
Description: 40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Oxycodone
Description: IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
Study: NCT03994276

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
Study: NCT01339663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: Receive T-APC via IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
Study: NCT00512382

Intervention type: DEVICE
Intervention: WEEM - Wheezy Monitoring
Description: loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.

Intervention type: DEVICE
Intervention: WEEM - Wheezy Monitoring
Description: loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
Study: NCT03805100

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection
Study: NCT02307266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care + supplementary education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care + additional visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Study: NCT02291770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
Study: NCT03233230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2591 25 mg QD
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 75 mg QD
Description: Participants received 75 mg of M2951 orally QD for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 50 mg BID
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M2951 orally for 12 weeks.
Study: NCT01179698

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Navigation surgery
Description: In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Navigation system
Description: In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
Study: NCT00658645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 20 mg daily, encapsulated tablets, orally, 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablets, orally, 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 600 mg daily, encapsulated tablets, orally, 12 months
Study: NCT02454660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS (Text messages)
Description: Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
Study: NCT00167687

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prazosin
Description: Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg
Study: NCT03063840

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
Study: NCT04921020

Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken

Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken

Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken

Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken

Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken
Study: NCT00010192

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04607330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein liquid
Description: After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
Study: NCT01299259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
Study: NCT04544501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Targeted Video
Description: Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FORCE Fact Sheet
Description: A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.